Recent Updates
Recently added Catalysts

ADVM-022

Phase 2

Neovascular Age-related Macular Degeneration | Gene Therapies | Ophthalmology |Adverum Biotechnologies, Inc.|Trials Updated: Oct 27, 2026

ADVM-022 development status

Highest phase Phase 2
Registered trials 4 across 1 sponsor since Nov 2018

ADVM-022 target and mechanism

ModalityGene Therapies

Also known as AAV.7m8-aflibercept

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLEDDMC
Total Trials2
Total Enrollment99

FDA Designations

No designations recorded

ADVM-022 clinical trials

ADVM-022 · 2 trials · 2 indications

Phase 2 1Phase 1 1
NCT05536973Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]Neovascular Age-related Macular Degeneration
ACTIVE NOT_RECRUITING69 Analytics
PHASE2ACTIVE NOT_RECRUITING
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular Age-related Macular DegenerationUnlock trial analytics

Study Endpoints

Primary Endpoints

Incidence of ocular and non-ocular adverse events
Up to Week 52
Severity of ocular and non-ocular adverse events
Up to Week 52
Mean change in best corrected visual acuity (BCVA) from Baseline
Baseline up to Week 52

BCVA measured by Early Treatment Diabetic Retinopathy Study (ETDRS)

Type, severity, and incidence of ocular and systemic adverse events (AEs)
104 weeks

Secondary Endpoints

Percentage of participants from Baseline who lose/gain at least 5, 10 or 15 letters in BCVA
Baseline up to 5 years
Mean change in BCVA from Baseline
Baseline up to 5 years
Percentage of participants who are supplemental aflibercept injection-free
Baseline up to 5 years
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Dose 1EXPERIMENTALA single intravitreal injection of ADVM-022 2E11 vg/eye
Dose 2EXPERIMENTALA single intravitreal injection of ADVM-022 6E10 vg/eye

Interventions

NameTypeDescription
ADVM-022GENETICA single IVT injection of 2E11 vg/eye ADVM-022 dose in combination with one (1) of four (4) corticosteroid treatment regimens
Unlock Study Design Details

Eligibility Criteria

Age Range50 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites39

Inclusion Criteria: * Male or female participants, ≥ 50 years of age * Willing and able to provide written, signed informed consent for this study * Demonstrated a meaningful response to anti-VEGF therapy * Participants must be under active anti-VEGF treatment for wet AMD and received a minimum of ...

Countries:United StatesFranceUnited Kingdom
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWOct 27, 2026NCT05536973lastUpdatePostDate: changed
LOWOct 27, 2026NCT05536973lastUpdatePostDate: changed

Frequently asked questions about ADVM-022

What is ADVM-022 used for?

ADVM-022 is an investigational gene therapy being developed for neovascular age-related macular degeneration, also called wet AMD. It is designed as an intravitreal treatment for patients with this form of retinal disease, which is the condition studied across its clinical program.

Who is developing ADVM-022?

ADVM-022 is being developed by Adverum Biotechnologies, Inc., a company that trades under the ticker ADVM. Adverum is the sponsor of the clinical program evaluating the gene therapy in patients with neovascular age-related macular degeneration.

What phase is ADVM-022 in?

ADVM-022 is in Phase 2 clinical development. Its Phase 2 study is the LUNA trial, which is active and not currently recruiting. An earlier Phase 1 study of ADVM-022 in wet AMD has been completed. ADVM-022 is investigational and has not been approved by the FDA.

What clinical trials is ADVM-022 in?

ADVM-022 has been studied in two clinical trials. The Phase 2 LUNA trial, NCT05536973, is active and not recruiting and enrolled 69 treatment-experienced patients with neovascular age-related macular degeneration across the United States, France, and the United Kingdom. The completed Phase 1 trial, NCT03748784, enrolled 30 patients in the United States.

Is the LUNA trial of ADVM-022 randomized and controlled?

Yes. The Phase 2 LUNA trial of ADVM-022, NCT05536973, is a randomized, double-blind, controlled study. It enrolled 69 treatment-experienced patients with neovascular age-related macular degeneration who were at least 50 years of age, and it is active but no longer recruiting participants.

What kind of therapy is ADVM-022?

ADVM-022 is a gene therapy administered by intravitreal injection, meaning it is delivered into the eye. It is being developed for neovascular age-related macular degeneration and is evaluated in clinical trials that enroll patients with wet AMD who have already received treatment.